Top Markets
#1 Islamic Coin Islamic Coin +152.68%
#2 Bitway Bitway +51.39%
#3 Starpower Starpower +38.71%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +37.80%
#5 Pons Pons +32.85%
#6 aelf aelf +28.46%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.94%
#8 SkyAI SkyAI +18.39%
#9 Ocean Protocol Ocean Protocol +17.58%
#10 Decred Decred +13.97%
Coin of the day
Islamic Coin Islamic Coin
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Modalis Therapeutics Corporation Modalis Therapeutics Corporation

Modalis Therapeutics Corporation

4883
Rang in Aktien #29675
Modalis Therapeutics Corporation focuses on discovering and developing... Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
Aktienkurs
$0.20877985
Marktkapitalisierung
$20.11M
Veränderung (1 Tag)
-3.03%
Veränderung (1 Jahr)
-66.13%
Land
JP
Handel Modalis Therapeutics Corporation (4883)

Kategorie

Healthcare
P/S-Verhältnis für Modalis Therapeutics Corporation (4883)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Modalis Therapeutics Corporation beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Modalis Therapeutics Corporation von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR